Conmed (NYSE: CNMD) reported Q3 EPS of $1.05, $0.06 better than the analyst estimate of $0.99. Revenue for the quarter came in at $316.7 million versus the consensus estimate of $318.15 million.

GUIDANCE:

Conmed sees FY2024 EPS of $4.00-$4.05, versus the consensus of $3.99. Conmed sees FY2024 revenue of $1.3-1.31 billion, versus the consensus of $1.31 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.